These pathway redundancies could be addressed by Akt degraders like INY-03-041, which was initially developed for oncology, and leverages short-term, high-intensity therapy to achieve rapid systemic Akt depletion, suppressing tumor growth. Here, AKT1 is linked to neoplasm.